文献速递瓣膜外科先天性心脏病外科

成人Ross术后肺动脉瓣远期功能:443例分析

Pulmonary Valve Function Late After Ross Procedure in 443 Adult Patients.
PubMed 文献 · Ann Thorac Surg · 2019-09-10

该回顾性研究纳入1992至2018年443例接受Ross手术的成人患者,术中均使用冷冻保存的肺动脉同种移植物。结果显示肺动脉瓣远期功能良好,20年免于再干预率96.6%,免于显著功能障碍率78.3%,未发现影响瓣膜耐久性的危险因素。

要点

  • 成人Ross术后肺动脉同种移植物20年免于再干预率96.6%。
  • 20年免于显著肺动脉瓣功能障碍率为78.3%。
  • 未识别出影响肺动脉瓣耐久性的危险因素。

核心结论

  • 在成人Ross手术中,肺动脉同种移植物提供优秀的远期功能,再干预罕见且显著功能障碍不常见。

研究设计与样本

  • 采用Kaplan-Meier法计算免于结局事件率,Cox回归分析瓣膜失败危险因素。

主要发现

  • 手术时平均年龄39岁(范围15-66岁),手术死亡1例(0.2%,1/443)。
  • 9例患者因感染性心内膜炎(n=4)、重度肺动脉狭窄(n=4)或重度肺动脉反流(n=1)在Ross术后平均6.1年(范围1-12年)接受肺动脉同种移植物再干预。
  • 免于肺动脉同种移植物再干预率在5、10、15、20年分别为98.9%(95%CI 97.1%-99.6%)、97.7%(95%CI 95.1%-98.9%)、96.6%(95%CI 93.3%-98.3%)、96.6%(95%CI 93.3%-98.3%)。
  • 免于肺动脉同种移植物功能障碍(至少中度肺动脉反流和/或平均收缩期压差≥25 mmHg和/或再干预)率在5、10、15、20年分别为94.5%(95%CI 91.6%-96.4%)、88.1%(95%CI 83.6%-91.4%)、84.9%(95%CI 79.6%-88.9%)、78.3%(95%CI 69.5%-84.9%)。
  • 未发现影响肺动脉瓣耐久性的危险因素。

临床怎么用

  • 对于接受Ross手术的成人患者,肺动脉同种移植物远期耐久性良好,支持其作为肺动脉瓣替代物的选择。
  • 术后远期需关注感染性心内膜炎、肺动脉狭窄及反流等可能导致再干预的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on long-term pulmonary valve function after the Ross procedure. This study sought to determine the long-term function of the pulmonary valve in 443 consecutive adult patients who underwent a Ross procedure. METHODS: All 443 patients who underwent a Ross procedure between November 1992 and March 2018 were reviewed retrospectively. All underwent pulmonary valve replacement using a cryopreserved pulmonary allograft. Freedom from the study's outcomes were calculated using Kaplan Meier survival. Risk factors for valve failure were analyzed using Cox regression. RESULTS: Mean age at time of operation was 39 years (range: 15-66 years). There was 1 (0.2%, 1 of 443) operative mortality. Nine patients required reintervention on the pulmonary allograft at a mean 6.1 years (range: 1-12 years) after Ross procedure. Patients required pulmonary allograft reintervention for infective endocarditis (n = 4), severe pulmonary stenosis (n = 4), or severe pulmonary regurgitation (n = 1). Freedom from pulmonary allograft reintervention was 98.9% (95% confidence interval [CI] 97.1%-99.6%), 97.7% (95% CI 95.1%-98.9%), 96.6% (95% CI 93.3%-98.3%), and 96.6% (95% CI 93.3%-98.3%) at 5, 10, 15, and 20 years, respectively. Freedom from pulmonary allograft dysfunction (at least moderate pulmonary regurgitation and/or mean systolic gradient ≥ 25 mm Hg and/or reintervention) was 94.5% (95% CI 91.6%-96.4%), 88.1% (95% CI 83.6%-91.4%), 84.9% (95% CI 79.6%-88.9%), and 78.3% (95% CI 69.5%-84.9%) at 5, 10, 15, and 20 years, respectively. No risk factors were identified to influence pulmonary valve durability. CONCLUSIONS: The pulmonary valve allograft gives excellent long-term function when used in adults undergoing the Ross procedure. Reintervention on the pulmonary valve is rare and significant pulmonary allograft dysfunction is uncommon.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Fricke TA, Skillington PD, Shi WY, et al. Pulmonary Valve Function Late After Ross Procedure in 443 Adult Patients. Ann Thorac Surg. 2019. PMID: 31518586. doi:10.1016/j.athoracsur.2019.07.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。